Miracle Mile Advisors LLC Buys 1,074 Shares of Edwards Lifesciences Co. (NYSE:EW)

Miracle Mile Advisors LLC grew its stake in Edwards Lifesciences Co. (NYSE:EWFree Report) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,371 shares of the medical research company’s stock after purchasing an additional 1,074 shares during the period. Miracle Mile Advisors LLC’s holdings in Edwards Lifesciences were worth $715,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Nordea Investment Management AB grew its stake in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares during the period. Versor Investments LP grew its position in Edwards Lifesciences by 83.3% during the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after acquiring an additional 2,043 shares during the last quarter. Gateway Investment Advisers LLC grew its position in Edwards Lifesciences by 12.2% during the 4th quarter. Gateway Investment Advisers LLC now owns 253,337 shares of the medical research company’s stock worth $19,317,000 after acquiring an additional 27,519 shares during the last quarter. US Bancorp DE grew its position in Edwards Lifesciences by 0.6% during the 3rd quarter. US Bancorp DE now owns 850,257 shares of the medical research company’s stock worth $58,906,000 after acquiring an additional 5,409 shares during the last quarter. Finally, West Coast Financial LLC grew its position in Edwards Lifesciences by 11.7% during the 4th quarter. West Coast Financial LLC now owns 143,644 shares of the medical research company’s stock worth $10,953,000 after acquiring an additional 15,018 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Evercore ISI lowered Edwards Lifesciences from an “outperform” rating to an “in-line” rating and decreased their price target for the stock from $80.00 to $77.00 in a research report on Thursday, January 4th. Stifel Nicolaus increased their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research report on Wednesday, February 7th. Truist Financial increased their price objective on Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Finally, Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $88.80.

Get Our Latest Analysis on EW

Edwards Lifesciences Stock Performance

EW stock opened at $94.30 on Wednesday. The business’s fifty day moving average is $87.13 and its 200-day moving average is $76.46. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The company has a market cap of $56.76 billion, a P/E ratio of 41.00, a price-to-earnings-growth ratio of 4.73 and a beta of 1.05. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 EPS. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares in the company, valued at approximately $2,980,774.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 189,604 shares of company stock valued at $16,022,982 in the last 90 days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.